Gut and Liver is an international journal of gastroenterology, focusing on the gastrointestinal tract, liver, biliary tree, pancreas, motility, and neurogastroenterology. Gut atnd Liver delivers up-to-date, authoritative papers on both clinical and research-based topics in gastroenterology. The Journal publishes original articles, case reports, brief communications, letters to the editor and invited review articles in the field of gastroenterology. The Journal is operated by internationally renowned editorial boards and designed to provide a global opportunity to promote academic developments in the field of gastroenterology and hepatology. +MORE
Yong Chan Lee |
Professor of Medicine Director, Gastrointestinal Research Laboratory Veterans Affairs Medical Center, Univ. California San Francisco San Francisco, USA |
Jong Pil Im | Seoul National University College of Medicine, Seoul, Korea |
Robert S. Bresalier | University of Texas M. D. Anderson Cancer Center, Houston, USA |
Steven H. Itzkowitz | Mount Sinai Medical Center, NY, USA |
All papers submitted to Gut and Liver are reviewed by the editorial team before being sent out for an external peer review to rule out papers that have low priority, insufficient originality, scientific flaws, or the absence of a message of importance to the readers of the Journal. A decision about these papers will usually be made within two or three weeks.
The remaining articles are usually sent to two reviewers. It would be very helpful if you could suggest a selection of reviewers and include their contact details. We may not always use the reviewers you recommend, but suggesting reviewers will make our reviewer database much richer; in the end, everyone will benefit. We reserve the right to return manuscripts in which no reviewers are suggested.
The final responsibility for the decision to accept or reject lies with the editors. In many cases, papers may be rejected despite favorable reviews because of editorial policy or a lack of space. The editor retains the right to determine publication priorities, the style of the paper, and to request, if necessary, that the material submitted be shortened for publication.
Correspondence to: Se Woo Park
ORCID https://orcid.org/0000-0003-1603-7468
E-mail britnepak@hallym.or.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Gut Liver 2021;15(5):643-645. https://doi.org/10.5009/gnl210402
Published online September 15, 2021, Published date September 15, 2021
Copyright © Gut and Liver.
Endoscopic ultrasound (EUS)-guided tissue acquisition (TA) of pancreatic solid tumor has been considered a standard approach for establishment of an accurate diagnosis and personalized therapeutic plan with rare adverse events.However, it has still limitations such as low negative predict value which cannot guarantee no malignancy in final diagnosis in cases that were initially classified as negative results despite recent innovation of newly designed needle and development of new endoscopic techniques. Recently, histologic core by EUS-guided fine needle biopsy (FNB) can facilitate an accurate differential diagnosis of various pancreatic solid tumors by specialized immunohistochemistry (IHC) staining in the current personalized medicine era.1 Despite this advancement of EUS-TA of pancreatic solid tumors, many technical aspects still require clinical standardization. Among these, the application of suction on the needle mount can be theoretically a standard practice based on the hypothesis that negative pressure by syringe would increase cellularity and further diagnostic accuracy. More recently, alternative capillary-pressure technique by pulling the needle stylet slowly during to-and-pro movement has been introduced. This technique called “capillary aspiration” or “slow-pull-back method” can result in improved diagnostic accuracy by better cellularity and lesser blood contamination.
Despite the mainstream nature of the practice, a widespread approach between standard suction and new slow-pull-back method has not yet been established. Therefore, clinical practice surrounding suction during EUS-TA including EUS-guided fine needle aspiration (FNA) and FNB vary considerably among training system of each institution and individual experience of physicians. Recent clinical guideline2 suggests that routine application of standard suction can be recommended in tumors with poor cellularity such as chronic pancreatitis or ductal adenocarcinoma, while it cannot be recommended in tumors which may contain rich cellularity with high vascularity or extensive necrosis. Moreover, the slow-pull-back method may be more effective regarding a procurement of adequate histologic core with fewer needle passes.
In the previous issue of
Recent randomized trial5 comparing suction and no-suction for pancreatic tumor reported that the application of suction resulted in higher cellularity but higher blood contamination. Therefore, suction can decrease the quality of sample due to the higher risk of blood contamination. In contrast to standard suction method, slow-pull-back method minimizes negative pressure by withdrawal the stylet continuously and slowly.6 In a recent RCT7 comparing three groups (the slow-pull-back vs standard suction vs non-suction method), the standard suction method had a higher blood contamination rate but did not result in increased histologic core procurement rate. Furthermore, the authors reported that the slow-pull-back method provided greater cellularity with lesser blood contamination compared with the other method, although the diagnostic adequacy based on histologic core tissue for malignancy was not differ between the groups. In addition, slow-pull-back method can provide more expeditious results based on lesser number of cytologic slides while guaranteeing results of higher cellularity and lower blood contamination in recent study.8
However, most important variable in recent EUS-TA is quality of histologic sampling not cellularity or blood contamination in the personalized medicine era. Better histologic and molecular evaluation of the pancreatic tumor can be expected in a tissue sample containing histologic core. In evaluation of histologic sample even in sample by cell block method, the cellularity or blood contamination cannot be an issue for determining of malignancy. Generally, liquid-based cytology, cell block, and histologic samples can all be used for IHC.9 Furthermore, IHC as well as molecular assays can play critical roles in differentiating benign or malignant lesions and the tracing the origin of metastatic tumors of the pancreas. Recent study evaluated the quantity of histologic sample by the computer-assisted measurement of the core fragment surface area. They reported that the quality of histologic sample had a strong correlation with quantity of sample measured by computer-assisted system, therefore, the larger histologic core specimens were able to improve the diagnostic accuracy.10
In conclusion, this meta-analysis has revealed that slow-pull-back method had several advantages of lesser blood contamination and better diagnostic accuracy. In my view, whether slow-pull-back or standard suction is better regarding blood contamination, endoscopists should pay attention to procurement of optimal histologic core based on special pathologic evaluation such as IHC not cytologic evaluation in the personalized medicine era.
See “A Meta-Analysis of Slow Pull versus Suction for Endoscopic Ultrasound-Guided Tissue Acquisition” by Yousuke Nakai, et al. on page 625, Vol. 15, No. 4, 2021
No potential conflict of interest relevant to this article was reported.
Gut and Liver 2021; 15(5): 643-645
Published online September 15, 2021 https://doi.org/10.5009/gnl210402
Copyright © Gut and Liver.
Division of Gastroenterology, Department of Internal Medicine, Hallym University College of Medicine, Hwaseong, Korea
Correspondence to:Se Woo Park
ORCID https://orcid.org/0000-0003-1603-7468
E-mail britnepak@hallym.or.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Endoscopic ultrasound (EUS)-guided tissue acquisition (TA) of pancreatic solid tumor has been considered a standard approach for establishment of an accurate diagnosis and personalized therapeutic plan with rare adverse events.However, it has still limitations such as low negative predict value which cannot guarantee no malignancy in final diagnosis in cases that were initially classified as negative results despite recent innovation of newly designed needle and development of new endoscopic techniques. Recently, histologic core by EUS-guided fine needle biopsy (FNB) can facilitate an accurate differential diagnosis of various pancreatic solid tumors by specialized immunohistochemistry (IHC) staining in the current personalized medicine era.1 Despite this advancement of EUS-TA of pancreatic solid tumors, many technical aspects still require clinical standardization. Among these, the application of suction on the needle mount can be theoretically a standard practice based on the hypothesis that negative pressure by syringe would increase cellularity and further diagnostic accuracy. More recently, alternative capillary-pressure technique by pulling the needle stylet slowly during to-and-pro movement has been introduced. This technique called “capillary aspiration” or “slow-pull-back method” can result in improved diagnostic accuracy by better cellularity and lesser blood contamination.
Despite the mainstream nature of the practice, a widespread approach between standard suction and new slow-pull-back method has not yet been established. Therefore, clinical practice surrounding suction during EUS-TA including EUS-guided fine needle aspiration (FNA) and FNB vary considerably among training system of each institution and individual experience of physicians. Recent clinical guideline2 suggests that routine application of standard suction can be recommended in tumors with poor cellularity such as chronic pancreatitis or ductal adenocarcinoma, while it cannot be recommended in tumors which may contain rich cellularity with high vascularity or extensive necrosis. Moreover, the slow-pull-back method may be more effective regarding a procurement of adequate histologic core with fewer needle passes.
In the previous issue of
Recent randomized trial5 comparing suction and no-suction for pancreatic tumor reported that the application of suction resulted in higher cellularity but higher blood contamination. Therefore, suction can decrease the quality of sample due to the higher risk of blood contamination. In contrast to standard suction method, slow-pull-back method minimizes negative pressure by withdrawal the stylet continuously and slowly.6 In a recent RCT7 comparing three groups (the slow-pull-back vs standard suction vs non-suction method), the standard suction method had a higher blood contamination rate but did not result in increased histologic core procurement rate. Furthermore, the authors reported that the slow-pull-back method provided greater cellularity with lesser blood contamination compared with the other method, although the diagnostic adequacy based on histologic core tissue for malignancy was not differ between the groups. In addition, slow-pull-back method can provide more expeditious results based on lesser number of cytologic slides while guaranteeing results of higher cellularity and lower blood contamination in recent study.8
However, most important variable in recent EUS-TA is quality of histologic sampling not cellularity or blood contamination in the personalized medicine era. Better histologic and molecular evaluation of the pancreatic tumor can be expected in a tissue sample containing histologic core. In evaluation of histologic sample even in sample by cell block method, the cellularity or blood contamination cannot be an issue for determining of malignancy. Generally, liquid-based cytology, cell block, and histologic samples can all be used for IHC.9 Furthermore, IHC as well as molecular assays can play critical roles in differentiating benign or malignant lesions and the tracing the origin of metastatic tumors of the pancreas. Recent study evaluated the quantity of histologic sample by the computer-assisted measurement of the core fragment surface area. They reported that the quality of histologic sample had a strong correlation with quantity of sample measured by computer-assisted system, therefore, the larger histologic core specimens were able to improve the diagnostic accuracy.10
In conclusion, this meta-analysis has revealed that slow-pull-back method had several advantages of lesser blood contamination and better diagnostic accuracy. In my view, whether slow-pull-back or standard suction is better regarding blood contamination, endoscopists should pay attention to procurement of optimal histologic core based on special pathologic evaluation such as IHC not cytologic evaluation in the personalized medicine era.
See “A Meta-Analysis of Slow Pull versus Suction for Endoscopic Ultrasound-Guided Tissue Acquisition” by Yousuke Nakai, et al. on page 625, Vol. 15, No. 4, 2021
No potential conflict of interest relevant to this article was reported.